sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_2349> biolink:category biolink:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_2349> ;
    rdf:predicate biolink:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB00865> ;
    a rdf:Statement ;
    rdfs:label "\"Benzphetamine hydrochloride tablets are contraindicated in patients with advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy to sympathomimetic amines, and glaucoma. Benzphetamine should not be given to patients who are in an agitated state or who have a history of drug abuse.  Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly or within 14 days following use of monoamine oxidase inhibitors. Benzphetamine hydrochloride should not be used concomitantly with other CNS stimulants.  Benzphetamine hydrochloride may cause fetal harm when administered to a pregnant woman. Amphetamines have been shown to be teratogenic and embryotoxic in mammals at high multiples of the human dose. Benzphetamine hydrochloride is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.  Insulin requirements in diabetes mellitus may be altered in association with use of anorexigenic drugs and the concomitant dietary restrictions.  Psychological disturbances have been reported in patients who receive an anorectic agent together with a restrictive dietary regime.  Caution is to be exercised in prescribing amphetamines for patients with even mild hypertension. The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage.  Amphetamines may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; the patient should therefore be cautioned accordingly.  Efficacy of benzphetamine hydrochloride tablets in combination with other anorectic agents has not been studied and the combined use may have the potential for serious cardiac problems. Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly or within 14 days following use of monoamine oxidase inhibitors. Benzphetamine hydrochloride should not be used concomitantly with other CNS stimulants.  Amphetamines may decrease the hypotensive effect of antihypertensives. Amphetamines may enhance the effects of tricyclic antidepressants. Urinary alkalinizing agents increase blood levels and decrease excretion of amphetamines. Urinary acidifying agents decrease blood levels and increase excretion of amphetamines.  Animal studies to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility have not been performed.  Pregnancy Category X (see CONTRAINDICATIONS Section).  Amphetamines are excreted in human milk. Mothers taking amphetamines should be advised to refrain from nursing. Safety and effectiveness in pediatric patients have not been established. Use of benzphetamine hydrochloride is not recommended in individuals under 12 years of age. Clinical studies of benzphetamine hydrochloride tablets did not include sufficient numbers of subjects aged 65 and over to establish safety and efficacy in this population. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.\"" ;
    biolink:provided_by <https://w3id.org/um/NeuroDKG> ;
    biolink:relation schema:MedicalContraindication .
  <https://identifiers.org/drugbank:DB00865> biolink:category biolink:Drug .
}